SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-041114
Filing Date
2023-02-16
Accepted
2023-02-16 16:32:04
Documents
12
Period of Report
2023-02-09
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d455266d8k.htm   iXBRL 8-K 43651
  Complete submission text file 0001193125-23-041114.txt   169467

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA clvsq-20230209.xsd EX-101.SCH 2532
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE clvsq-20230209_lab.xml EX-101.LAB 17969
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE clvsq-20230209_pre.xml EX-101.PRE 11251
6 EXTRACTED XBRL INSTANCE DOCUMENT d455266d8k_htm.xml XML 3507
Mailing Address 5500 FLATIRON PARKWAY SUITE 100 BOULDER CO 80301
Business Address 5500 FLATIRON PARKWAY SUITE 100 BOULDER CO 80301 (303) 625-5000
Clovis Oncology, Inc. (Filer) CIK: 0001466301 (see all company filings)

IRS No.: 900475355 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35347 | Film No.: 23638933
SIC: 2834 Pharmaceutical Preparations